An unsolved challenge in the development of antigen specific immunotherapies is determining the optimal antigens to target. Comprehension of antigen-MHC binding is paramount towards achieving this goal. Here, we present CASTELO, a combined machine learning-molecular dynamics (ML-MD) approach to design novel antigens of increased MHC binding affinity for a Type 1 diabetes (T1D)-implicated system. We build upon a small molecule lead optimization algorithm by training a convolutional variational autoencoder (CVAE) on MD trajectories of 48 different systems across 4 antigens and 4 HLA serotypes. We develop several new machine learning metrics including a structure-based anchor residue classification model as well as cluster comparison scores. ML-MD predictions agree well with experimental binding results and free energy perturbation-predicted binding affinities. Moreover, ML-MD metrics are independent of traditional MD stability metrics such as contact area and RMSF, which do not reflect binding affinity data. Our work supports the role of structure-based deep learning techniques in antigen specific immunotherapy design.
تحميل البحث